We wrapped up the week with the news that the Biden administration selected semaglutide (Ozempic, Wegovy, Rybelsus) to be on the next list of drugs selected for Medicare negotiations. We’ll have more below on what this means for President-elect Donald Trump and his pick to lead CMS, ...
GLP-1 agonist drugs treat diabetes by balancing blood glucose levels. Here’s our list of GLP-1 agonists, how they work, similarities and differences, and more.
Yes. Although acute studies may be of lesser importance in assessing the safety of human drugs,...
Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in widespread compounding of GLP-1 products that would otherwise be prohibited under the relevant stat...
Another downside is that these medications come with a hefty price tag. Thelist priceranges from $900 - $1350 per person per month, and these prices are not expected to go down. The surge in sales, popularity, and prevalence of these drugs is poised to create staggering costs for employers...
drugs work, they work for a lot of patients, they've made a significant change in a lot of people's lives, but that has resulted in a lot of challenges, because so much of the U.S. population is eligible for these medications. So much of the U.S. population either has type 2...
Glucagon-like peptide (GLP)-2 analogs are a class of drugs used for the prevention or treatment of patients with short bowel syndrome (SBS) who need intravenous nutrition and fluids.
However, caution should be exercised as to whether or not these drugs are appropriate for the management of Asian type 2 diabetes patients, which are primarily characterized by non‐obesity and impaired β‐cell function, as well as in that of elderly adults with type 2 diabetes, who tend to...
Here’s the real reason Ozempic-like weight-loss drugs are so popular Ozempic and Wegovy are trimming waistlines—and showing how quickly U.S. health care can turn into a gold rush Did your workplace make our list of the World's Most Admired Companies? Explore this year's list. About th...
For instance, it has been shown that anti-diabetic drugs counteracting insulin resistance (i.e. metformin) seem to decrease PDAC risk, whereas the ones aimed to circulating insulin enhancement (i.e. insulin analogs) manifest an increased risk [36,37,38,39]. Data on a novel class of anti-...